Document is current
Any future updates will be listed below
-
Authors
He, Jingjing
Liu, Boxin
Du, Xiaofeng
Wei, Yan
Kong, Desheng
Feng, Baofeng
Guo, Ruiyun
Asiamah, Ernest Amponsah
Griffin, Matthew D.
Hynes, Sean O.
Shen, Sanbing
Liu, Yan
Cui, Huixian
Ma, Jun https://orcid.org/0000-0003-2843-0769
O’Brien, Timothy
-
Funding
Funding for this research was provided by:
Graduate Innovation Funding Project of Hebei Province (CXZZBS2021072)
Natural Science Foundation of China (81801278)
China Scholarship Council (201608130015)
Natural Science Foundation of Hebei Province (H2019206637, H2015206409)
Key Natural Science Foundation of Hebei Province (H2020206557)
Hebei University Science and technology research project (ZD2019049)
Overseas researcher Program in Hebei Provincial Department of human resources and social security (C20190509)
Horizon 2020 Collaborative Health Project NEPHSTROM (634086)
Science Foundation Ireland (13/RC/2073_P2)
Investigator Programme (15/IA/3136)
- License Information
-
More Information
Article History
Received: 25 March 2023
Accepted: 24 January 2024
First Online: 5 March 2024
Declarations
:
: The experiments were conducted in accordance with the National Institutes of Health guidelines for the care of animals. The animal studies came from the project of "Effect and Mechanism of Mesenchymal Stem Cell in the Treatment of Diabetic Complications” and was approved by the Laboratory Animal Ethical and Welfare Committee of Hebei Medical University (Approval No. IACUC-Hebmu-2021035, Date: 8 December 2021).
: Not applicable.
: T O’Brien is a Director and Equity holder in Orbsen Therapeutics. Timothy O’Brien is the Co-Editor-in-Chief of the journal Stem Cell Research & Therapy, and he declares that he is not involved in the peer review nor decision making of this article. MD Griffin reports honoraria from the American Society of Nephrology; Hebei Medical University, China; Théa Pharma Ltd., Ireland; and Novo Nordisk; research funding from Orbsen Therapeutics Ltd.; and advisory roles as an Editorial Board member for the journals Transplantation and Frontiers in Pharmacology and an Associate Editor for Mayo Clinic Proceedings. The rest of the authors declare they do not have any competing interests.
